<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36546684</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>APOE2 Exacerbates TDP-43 Related Toxicity in the Absence of Alzheimer Pathology.</ArticleTitle><Pagination><StartPage>830</StartPage><EndPage>843</EndPage><MedlinePgn>830-843</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26580</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Recent evidence supports a link between increased TDP-43 burden and the presence of an APOE4 gene allele in Alzheimer's disease (AD); however, it is difficult to conclude the direct effect of APOE on TDP-43 pathology due to the presence of mixed AD pathologies. The goal of this study is to address how APOE isoforms impact TDP-43 pathology and related neurodegeneration in the absence of typical AD pathologies.</AbstractText><AbstractText Label="METHODS">We overexpressed human TDP-43 via viral transduction in humanized APOE2, APOE3, APOE4 mice, and murine Apoe-knockout (Apoe-KO) mice. Behavior tests were performed across ages. Animals were harvested at 11&#xa0;months of age and TDP-43 overexpression-related neurodegeneration and gliosis were assessed. To further address the human relevance, we analyzed the association of APOE with TDP-43 pathology in 160 postmortem brains from autopsy-confirmed amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with motor neuron disease (FTLD-MND) in the Mayo Clinic Brain Bank.</AbstractText><AbstractText Label="RESULTS">We found that TDP-43 overexpression induced motor function deficits, neuronal loss, and gliosis in the motor cortex, especially in APOE2 mice, with much milder or absent effects in APOE3, APOE4, or Apoe-KO mice. In the motor cortex of the ALS and FTLD-MND postmortem human brains, we found that the APOE2 allele was associated with more severe TDP-43-positive dystrophic neurites.</AbstractText><AbstractText Label="INTERPRETATION">Our data suggest a genotype-specific effect of APOE on TDP-43 proteinopathy and neurodegeneration in the absence of AD pathology, with the strongest association seen with APOE2. ANN NEUROL 2023;93:830-843.</AbstractText><CopyrightInformation>&#xa9; 2022 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meneses</LastName><ForeName>Axel D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Translational Science Graduate Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koga</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zonghua</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-5242-9608</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Leary</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fuyao</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3986-2412</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murakami</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Wenhui</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurti</LastName><ForeName>Aishe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckman</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0003-3770-9331</Identifier><AffiliationInfo><Affiliation>Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Launia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Manling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yixing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finch</LastName><ForeName>Nicole A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Melina J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delenclos</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeTure</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linares</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Nicholas B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Tadafumi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Blitterswijk</LastName><ForeName>Marka M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Long-Jun</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB Center for Molecular Neurology, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Owen A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0003-4813-756X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Na</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8648-9422</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG057181</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG069701</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG057181</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19AG069701</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053329">Apolipoprotein E2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053329" MajorTopicYN="N">Apolipoprotein E2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Potential Conflicts of Interest:</b> All authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36546684</ArticleId><ArticleId IdType="mid">NIHMS1920037</ArticleId><ArticleId IdType="pmc">PMC10471132</ArticleId><ArticleId IdType="doi">10.1002/ana.26580</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer&#x2019;s disease. Mol Neurodegener. 2019. Aug 2;14(1):32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018. Jul 1;141(7):2181&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006. Oct 6;314(5796):130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneses A, Koga S, O&#x2019;Leary J, Dickson DW, Bu G, Zhao N. TDP-43 Pathology in Alzheimer&#x2019;s Disease. Mol Neurodegener. 2021. Dec 20;16(1):84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691026</ArticleId><ArticleId IdType="pubmed">34930382</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol. 2007. May;61(5):435&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, et al. TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127(6):811&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino A, Takao M, Hatsuta H, et al. Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun. 2015. Jun 20;3:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473839</ArticleId><ArticleId IdType="pubmed">26091809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Schmitt FA, Lin Y, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain. 2011. May;134(Pt 5):1506&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097889</ArticleId><ArticleId IdType="pubmed">21596774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019. Jun 1;142(6):1503&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol. 2008. Jun;67(6):555&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg AM, Tosakulwong N, Lesnick TG, et al. Association of Apolipoprotein E epsilon4 With Transactive Response DNA-Binding Protein 43. JAMA Neurol. 2018. Nov 1;75(11):1347&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248121</ArticleId><ArticleId IdType="pubmed">30422173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, Yu L, White CC, et al. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study. Lancet Neurol. 2018. Sep;17(9):773&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6154505</ArticleId><ArticleId IdType="pubmed">30093249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G. Apolipoprotein E and its receptors in Alzheimer&#x2019;s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009. May;10(5):333&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908393</ArticleId><ArticleId IdType="pubmed">19339974</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019. Sep;15(9):501&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055192</ArticleId><ArticleId IdType="pubmed">31367008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Qiao W, Bu G. Apolipoprotein E, Receptors, and Modulation of Alzheimer&#x2019;s Disease. Biol Psychiatry. 2018. Feb 15;83(4):347&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599322</ArticleId><ArticleId IdType="pubmed">28434655</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer&#x2019;s disease. Mol Neurodegener. 2020. Jul 16;15(1):40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364557</ArticleId><ArticleId IdType="pubmed">32677986</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg TE, Huey ED, Devanand DP. Association of APOE e2 genotype with Alzheimer&#x2019;s and non-Alzheimer&#x2019;s neurodegenerative pathologies. Nat Commun. 2020. Sep 18;11(1):4727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7501268</ArticleId><ArticleId IdType="pubmed">32948752</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Ren Y, Yamazaki Y, et al. Alzheimer&#x2019;s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. Neuron. 2020. Jun 3;106(5):727&#x2013;42 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388065</ArticleId><ArticleId IdType="pubmed">32199103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Attrebi ON, Ren Y, et al. APOE4 exacerbates alpha-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med. 2020. Feb 5;12(529).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8309690</ArticleId><ArticleId IdType="pubmed">32024798</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Van Ingelgom AJ, et al. APOE epsilon2 is associated with increased tau pathology in primary tauopathy. Nat Commun. 2018. Oct 22;9(1):4388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197187</ArticleId><ArticleId IdType="pubmed">30348994</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson KL, Dayton RD, Klein RL. AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats. Mol Ther Methods Clin Dev. 2015;2:15036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588447</ArticleId><ArticleId IdType="pubmed">26445725</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M, Liu YU, Zhao S, et al. TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration. Nat Neurosci. 2022. Jan;25(1):26&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8741737</ArticleId><ArticleId IdType="pubmed">34916658</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Zhou X, Murakami A, et al. Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology. Neuropathol Appl Neurobiol. 2022. Feb;48(2):e12778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9300011</ArticleId><ArticleId IdType="pubmed">34823271</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Lin WL, Walton RL, Ross OA, Dickson DW. TDP-43 pathology in multiple system atrophy: colocalization of TDP-43 and alpha-synuclein in glial cytoplasmic inclusions. Neuropathol Appl Neurobiol. 2018. Dec;44(7):707&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6191374</ArticleId><ArticleId IdType="pubmed">29660838</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Kouri N, Walton RL, et al. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathol. 2018. Sep;136(3):389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309287</ArticleId><ArticleId IdType="pubmed">29926172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Arakawa H, Wang L, et al. Motor-Coordinative and Cognitive Dysfunction Caused by Mutant TDP-43 Could Be Reversed by Inhibiting Its Mitochondrial Localization. Mol Ther. 2017. Jan 4;25(1):127&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363201</ArticleId><ArticleId IdType="pubmed">28129109</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Tong J, Bi F, Zhou H, Xia XG. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest. 2012. Jan;122(1):107&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248298</ArticleId><ArticleId IdType="pubmed">22156203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S, Carr K, Reiley L, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6:171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef A, Robinson JL, Irwin DJ, et al. Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. Acta Neuropathol Commun. 2017. Sep 6;5(1):68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586052</ArticleId><ArticleId IdType="pubmed">28877758</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020. Aug 15;15(1):45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Velmeshev D, Hashimoto K, et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. Nature. 2020. Dec;588(7838):459&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746606</ArticleId><ArticleId IdType="pubmed">32866962</ArticleId></ArticleIdList></Reference><Reference><Citation>Wareham LK, Liddelow SA, Temple S, et al. Solving neurodegeneration: common mechanisms and strategies for new treatments. Mol Neurodegener. 2022. Mar 21;17(1):23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935795</ArticleId><ArticleId IdType="pubmed">35313950</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Beckers J, Gossye H, Van Damme P. The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD. Mol Neurodegener. 2022. Mar 18;17(1):22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8932121</ArticleId><ArticleId IdType="pubmed">35303907</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer&#x2019;s disease. Mol Neurodegener. 2020. Nov 4;15(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7640652</ArticleId><ArticleId IdType="pubmed">33148290</ArticleId></ArticleIdList></Reference><Reference><Citation>Seto M, Weiner RL, Dumitrescu L, Hohman TJ. Protective genes and pathways in Alzheimer&#x2019;s disease: moving towards precision interventions. Mol Neurodegener. 2021. Apr 29;16(1):29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086309</ArticleId><ArticleId IdType="pubmed">33926499</ArticleId></ArticleIdList></Reference><Reference><Citation>Chornenkyy Y, Fardo DW, Nelson PT. Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. Lab Invest. 2019. Jul;99(7):993&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6609463</ArticleId><ArticleId IdType="pubmed">30742063</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain N, Chen-Plotkin AS. Genetic Modifiers in Neurodegeneration. Curr Genet Med Rep. 2018. Mar;6(1):11&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6028053</ArticleId><ArticleId IdType="pubmed">29977663</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006. Jun;59(6):952&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629792</ArticleId><ArticleId IdType="pubmed">16718704</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y, Iwasaki Y, Ishigaki S, et al. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain. 2022. Mar 11.</Citation><ArticleIdList><ArticleId IdType="pubmed">35274674</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung DC, Roemer S, Petrucelli L, Dickson DW. Cellular and pathological heterogeneity of primary tauopathies. Mol Neurodegener. 2021. Aug 23;16(1):57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381569</ArticleId><ArticleId IdType="pubmed">34425874</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cairns NJ, Grossman M, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015. Apr;129(4):469&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369168</ArticleId><ArticleId IdType="pubmed">25549971</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A, Ferrari R, Heutink P, et al. Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia. Brain. 2017. May 1;140(5):1437&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28387812</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino E, Vacca A, Govone F, De Martino P, Pinessi L, Rainero I. Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: a meta-analysis. Alzheimers Dement. 2013. Nov;9(6):706&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">23688578</ArticleId></ArticleIdList></Reference><Reference><Citation>Verpillat P, Camuzat A, Hannequin D, et al. Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. Eur J Hum Genet. 2002. Jul;10(7):399&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">12107813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Brunetti M, Barberis M, et al. The Role of APOE in the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2016. Apr;73(4):425&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26903389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the Role of TREM2 in Alzheimer&#x2019;s Disease. Neuron. 2017. Apr 19;94(2):237&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Magno L, Bunney TD, Mead E, Svensson F, Bictash MN. TREM2/PLCgamma2 signalling in immune cells: function, structural insight, and potential therapeutic modulation. Mol Neurodegener. 2021. Apr 6;16(1):22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8022522</ArticleId><ArticleId IdType="pubmed">33823896</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, Restrepo CR, Khan T, et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat Neurosci. 2018. Mar;21(3):329&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857237</ArticleId><ArticleId IdType="pubmed">29463850</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M, Zhao S, Bosco DB, Nguyen A, Wu LJ. Microglial TREM2 in amyotrophic lateral sclerosis. Dev Neurobiol. 2022. Jan;82(1):125&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8898078</ArticleId><ArticleId IdType="pubmed">34874625</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, Liu CC, Painter MM, et al. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem. 2015. Oct 23;290(43):26043&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, DeVaux LB, Farzan M. The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J Biol Chem. 2015. Oct 23;290(43):26033&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimenova AA, Marcora E, Goate AM. A Tale of Two Genes: Microglial Apoe and Trem2. Immunity. 2017. Sep 19;47(3):398&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">28930654</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017. Jun 15;169(7):1276&#x2013;90 e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017. Sep 19;47(3):566&#x2013;81 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Martino AT, Markusic DM. Immune Response Mechanisms against AAV Vectors in Animal Models. Mol Ther Methods Clin Dev. 2020. Jun 12;17:198&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6965504</ArticleId><ArticleId IdType="pubmed">31970198</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamudio F, Loon AR, Smeltzer S, et al. TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model. J Neuroinflammation. 2020. Sep 26;17(1):283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7519496</ArticleId><ArticleId IdType="pubmed">32979923</ArticleId></ArticleIdList></Reference><Reference><Citation>Damisah EC, Rai A, Grutzendler J. TREM2: Modulator of Lipid Metabolism in Microglia. Neuron. 2020. Mar 4;105(5):759&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">32135085</ArticleId></ArticleIdList></Reference><Reference><Citation>Claes C, Danhash EP, Hasselmann J, et al. Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer&#x2019;s disease. Mol Neurodegener. 2021. Jul 23;16(1):50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8305935</ArticleId><ArticleId IdType="pubmed">34301296</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang PM, Ling J, Jeong YH, Price DL, Aja SM, Wong PC. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc Natl Acad Sci U S A. 2010. Sep 14;107(37):16320&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941284</ArticleId><ArticleId IdType="pubmed">20660762</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings NR, Puttaparthi K, Dowling KJ, et al. TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. PLoS One. 2013;8(8):e71793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742534</ArticleId><ArticleId IdType="pubmed">23967244</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Khan R, Polymenidou M, Schulz PE. Disease-modifying effects of metabolic perturbations in ALS/FTLD. Mol Neurodegener. 2018. Dec 4;13(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278047</ArticleId><ArticleId IdType="pubmed">30509290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, De Conti L, Avendano-Vazquez SE, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011. Jan 19;30(2):277&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Spiller KJ, Ge G, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015. Nov;130(5):643&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>